Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Minoryx Therapeutics and Sperogenix Therapeutics…

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news

Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

Minoryx Therapeutics receives US FDA…

Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia

Minoryx Therapeutics receives Orphan Drug…

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics receives FDA Orphan…

Minoryx: Un axe Espagne-Belgique pour sauter la barrière

Minoryx News Article: Un axe…

Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics completes enrollment in…

First patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

Mataró, Barcelona, Spain and Charleroi,…